#### AFRL-HE-WP-TR-2000-0076



# UNITED STATES AIR FORCE RESEARCH LABORATORY

# **EFFECTS OF PERCHLORATE ON**

## THYROIDAL UPTAKE OF IODIDE WITH

## **CORRESPONDING HORMONAL**

# **CHANGES**

K.O. Yu P.N. Todd S.M. Young D.R. Mattie J.W. Fisher OPERATIONAL TOXICOLOGY BRANCH, AFRL/HEST 2856 G STREET WRIGHT PATTERSON AFB, OH 45433-7400

L. Narayanan R.J. Godfrey MANTECH-GEO-CENTERS JOINT VENTURE P.O. BOX 31009 DAYTON, OH 45437

**T.R. Sterner** OPERATIONAL TECHNOLOGIES CORP. 1370 N FAIRFIELD ROAD, SUITE A BEAVERCREEK, OH 45432

> **C. Goodyear** STATISTICAL CONSULTANT WAYNESVILLE, OH

20060630296

July 2000 Interim Report - June 1998 - June 2000

Human Effectiveness Directorate Deployment and Sustainment Division Operational Toxicology Branch 2856 G Street Wright-Patterson AFB OH 45433-7400

Approved for public release; distribution is unlimited.

STINFO COPY

#### NOTICES

When US Government drawings, specifications or other data are used for any purpose other than a definitely related Government procurement operation, the Government thereby incurs no responsibility nor any obligation whatsoever, and the fact that the Government may have formulated, furnished, or in any way supplied the said drawings, specifications, or other data is not to be regarded by implication or otherwise, as in any manner licensing the holder or any other person or corporation, or conveying any rights or permission to manufacture, use, or sell any patented invention that may in any way be related thereto.

Please do not request copies of this report from the Air Force Research Laboratory. Additional copies may be purchased from:

National Technical Information Service 5285 Port Royal Road Springfield, Virginia 22161

Federal Government agencies and their contractors registered with the Defense Technical Information Center should direct requests for copies of this report to:

Defense Technical Information Service 8725 John J. Kingman Rd., Ste 0944 Ft. Belvoir, Virginia 22060-6218

#### DISCLAIMER

This Technical Report is published as received and has not been edited by the Technical Editing Staff of the Air Force Research Laboratory.

#### **TECHNICAL REVIEW AND APPROVAL**

#### AFRL-HE-WP-TR-2000-0076

The animal use described in this study was conducted in accordance with the principles stated in the "Guide for the Care and Use of Laboratory Animals", National Research Council, 1996, and the Animal Welfare Act of 1966, as amended.

This report has been reviewed by the Office of Public Affairs (PA) and is releasable to the National Technical Information Service (NTIS). At NTIS, it will be available to the general public, including foreign nations.

This technical report has been reviewed and is approved for publication.

FOR THE DIRECTOR

Dwidk. Matte

**DAVID R. MATTIE**, Ph.D. Acting Branch Chief, Operational Toxicology Branch Air Force Research Laboratory

#### **REPORT DOCUMENTATION PAGE**

.

Form Approved		
OMB No.	0704-0188	

		I	
Public reporting burden for this collection of in gathering and maintaining the data needed, ar collection of information, including suggestion Davis Highway, Suite 1204, Arlington, VA 22	nformation is estimated to average 1 hour pe nd completing and reviewing the collection o is for reducing this burden, to Washington H 2202-4302, and to the Office of Management	r response, including the time for review f information. Send comments regarding eadquarters Services, Directorate for Info and Budget, Paperwork Reduction Proje	ing instructions, searching existing data sources, this burden estimate or any other aspect of this ormation Operations and Reports, 1215 Jeffeson ct (0704-0188), Washington, DC 20503.
1. AGENCY USE ONLY (Leave bla		3. REPORT TYPE AND D	
	July 2000	Interim Repor	t - June 1998 - June 2000
			FUNDING NUMBERS
Effects of Perchlorate on Thyroi	idal Uptake of Iodide with Corr	esponding Hormonal Co	ontract F41624-96-C-9010
Changes PE			E 62202F
P P			
K.O. Yu, L. Narayanan, R.J. Godfrey, P.N. Todd, C. Goodyear, T.R. Sterner, T.A.			
Bausman, S.M. Young, D.R. Mattie, J.W. Fisher			U 1710D418
Dausinan, S.W. Toung, D.R. W			
7. PERFORMING ORGANIZATION	NAME(S) AND ADDRESS(ES)		PERFORMING ORGANIZATION
ManTech-Geo-Centers Joint Ver		0.	REPORT NUMBER
	indie		
PO Box 31009			
Dayton, OH 45437			
9. SPONSORING/MONITORING A	GENCY NAME(S) AND ADDRESS		. SPONSORING/MONITORING
9. SPONSORING/MONITORING A Human Effectiveness Directorate		10	AGENCY REPORT NUMBER
	e		
Air Force Research Laboratory	22 7400		AFRL-HE-WP-TR-2000-0076
Wright-Patterson AFB, OH 4543	33-7400		
11. SUPPLEMENTARY NOTES			
TI. SUPPLEMENTART NOTES			
12a. DISTRIBUTION AVAILABILITY	STATEMENT	12	b. DISTRIBUTION CODE
Approved for public release; distribution is unlimited.			
10 ADOTDAOT (14		<b>_</b>	
13. ABSTRACT (Maximum 200 wo	-	multing in reduced thursdal	hormone synthesis. The objective
	-	•	
of this project was to conduct a s			
thyroid and its effects on the syn			_
performed to investigate its kine		v	· · · · · · · · · · · · · · · · · · ·
perchlorate/kg via tail vein, chal	lenged with 125I with carrier a	t 2 h post dosing, and euthan	nized at predetermined time
points. Three groups $(n=6 \text{ per } g)$	group) of 1-, 5-, and 14-day dri	nking water studies were per	formed at different levels of
perchlorate (0, 1, 3 and 10 mg/k	g). At the end of exposure, rat	s were challenged once by ta	il vein injection with 125I with
carrier. Dose-related inhibition of	of thyroid iodide uptake after a	single iv dose of perchlorate	, and both dose- and time-
dependent changes in inhibition of thyroid iodide uptake were observed in drinking water studies. In both the single dose and			
drinking water studies, TSH and free T4 levels were elevated with T4 levels decreased. Serum T3 levels in drinking water			
studies remained unchanged in a		And a r revers devicased. Set	and is so to is in definiting water
studies remained unenanged in a	it doshig groups.		
14. SUBJECT TERMS			15. NUMBER OF PAGES
Perchlorate TSH	r-counter		27
Thyroid gland T4	ion-chromatography		16. PRICE CODE
Iodide uptake T3			
	18. SECURITY CLASSIFICATION	19. SECURITY CLASSIFICAT	ION 20. LIMITATION OF ABSTRACT
OF REPORT	OF THIS PAGE	OF ABSTRACT	
UNCLASSIFIED	UNCLASSIFIED	UNCLASSIFIED	UL
			Standard Form 298 (Rev. 2-89) (EG)

.

# THIS PAGE INTENTIONALLY LEFT BLANK.

· ·

ii

INTRODUCTION	1
METHODS	3
Chemicals	3
Animals	
Animal Studies	3
Intravenous Dosing studies	3
<sup>125</sup> I and <sup>125</sup> I with carrier	3
Perchlorate with <sup>125</sup> I (with carrier) challenge	4
Perchlorate with thyroid hormone profile	4
Drinking water studies	
Perchlorate with <sup>125</sup> I (with carrier) challenge	4
Perchlorate with thyroid hormone profile	
Analytical Procedures	
<sup>125</sup> I (with carrier) Analysis in tissues	
High pressure liquid chromatography (HPLC) analysis of perchlorate	5
HPLC conditions	
Analysis of TSH and thyroid hormones	5
Statistical Analysis	-
RESULTS	7
Intravenous Administration of Iodide and Perchlorate	7
Perchlorate drinking water studies	15
DISCUSSION	
REFERENCES	

## TABLE OF CONTENTS

## LIST OF FIGURES

Figure 1. Percentages of bound iodide in the thyroid of male rats dosed with <sup>125</sup> I (carrier-
free) and <sup>125</sup> I with carrier
Figure 2. Perchlorate levels in thyroid of male rats after single iv injection of perchlorate9
Figure 3. Perchlorate levels in serum of male rats after single iv injection of perchlorate10
Figure 4. Total iodine levels in the thyroid of male rats after a singe <i>iv</i> injection of
perchlorate, then <sup>125</sup> I with carrier at 2 hours post dosing12
Figure 5. Free iodide levels in serum of male rats after a single injection of perchlorate, then
<sup>125</sup> I with carrier at 2 hours post dosing
Figure 6. Levels of serum TSH and thyroid hormones of rats after <i>iv</i> injection of perchlorate
(3 mg/kg)14
Figure 7. Percent inhibition of iodide uptake in the thyroid relative to control. Rats were
provided perchlorate for 1, 5 or 14 days, and then challenged with <sup>125</sup> I with carrier
Figure 8. Hormonal changes by perchlorate in repeated doses at 0, 0., 1, 3 and 10 mg/kg for
1, 5 and 14 days exposure

## LIST OF TABLES

TABLE 1. HALF-LIVES (HOURS) OF TERMINAL PHASES OF PERCHLORATE IN	
THE THYROID AND SERUM	9
TABLE 2. PERCENT INHIBITION OF IODIDE UPTAKE IN THE THYROID GLAND	
OF SD RATS DOSED WITH PERCHLORATE	11

#### PREFACE

This study was conducted at the Air Force Research Laboratory, Human Effectiveness Directorate, Operational Toxicology Branch (AFRL/HEST). Work was performed under the following contracts and supervision: ManTech GEOCENTERS Joint Venture (F41624-96-C-9010, Program Manager: Dr. Darol Dodd, P.O. Box 31009, Dayton, Ohio 45437) and Operational Technologies Corporation (DAHA 90-06-D-0014, Manager: Dr. Peter Lurker, 1370 N. Fairfield Rd., Suite A, Beavercreek, Ohio 45432). Mr. Chuck Goodyear is a statistical consultant for AFRL, Human Effectiveness Directorate, Crew Systems Interface Division (AFRL/HEC), Wright-Patterson Air Force Base, Ohio.

The animals used in this study were handled in accordance with the principles stated in the *Guide* for the Care and Use of Laboratory Animals, National Research Council, 1996, and the Animal Welfare Act of 1966, as amended.

### LIST OF ABBREVIATIONS AND ACRONYMS

ШØ	microgram
μg	microliter
μL	
μm	micrometer
$\gamma$ <sup>125</sup> I	gamma
<sup>125</sup> I	carrier-free iodide
AP	ammonium perchlorate
ClO <sub>4</sub> -	perchlorate anion
G	gravity
h	hour
HPLC	high pressure liquid chromatography
iv	intravenous
kg	kilogram
mg	milligram
min	minute
mL	milliliter
mm	millimeter
mM	milli-molar
n	sample size
NIS	sodium iodide symporter
RIA	radioimmunoassay
rpm	rotations per minute
SD	standard deviation
$T_3$	triiodothyronine
$T_4$	tetraiodothyronine or thyroxine
TBG	thyroxine binding globulin
TCA	trichloroacetic acid
Tg	thyroglobulin
TSH	thyroid stimulating hormone

#### EFFECTS OF PERCHLORATE ON THYROID UPTAKE OF IODIDE WITH CORRESPONDING HORMONAL CHANGES

#### **INTRODUCTION**

The perchlorate anion,  $ClO_4^-$ , acts as a competitive inhibitor of iodide uptake in the thyroid gland (Wolff, 1998). Its molecular size and charge are similar to iodide, an essential constituent for the thyroid hormones thyroxine (T<sub>4</sub>) and triiodothyronine (T<sub>3</sub>). The Na<sup>+</sup>/I<sup>-</sup> symporter (NIS), a protein channel located in the basolateral membrane of the thyroid follicular cells, actively transports iodide (Carrasco, 1993; Eskandari *et al.*, 1997). Iodide enters the follicular cells against an electrochemical gradient by a carrier-mediated mechanism driven by ATP (adenosine triphosphate). Perchlorate competes with iodide for uptake at this iodide-concentrating step (Goldman and Stanbury, 1973), potentially leading to hypothyroidism. As a result perchlorate has been used to treat hyperthyroidism (Wolff, 1998).

In the thyroid follicular cell, iodide passively diffuses across the apical membrane into the colloid, where inorganic iodide is oxidized to molecular iodine by thyroid peroxidase, a membrane-bound enzyme associated with the apical membrane (Nunez and Pommier, 1982). Iodination of tyrosyl residues of thyroglobulin (Tg) takes place in the colloid (called the organification of iodine) and coupling of iodotyrosine with Tg forms  $T_4$  and  $T_3$ . Thyroid hormones ( $T_4$  and  $T_3$ ) bound to Tg is the transported from the colloid into the follicle (Carraso, 1993). Although other tissues such as salivary gland, choroid plexus, gastric mucosa and mammary gland have iodide concentrating ability, synthesis of thyroid hormones takes place only in the thyroid gland (Wolff, 1998).

Proteolysis of Tg results in release of iodothyronines into the blood.  $T_4$  is the primary iodothyronine product of a normal thyroid and is converted to  $T_3$  by the enzyme 5'-deiodonase, located mainly in the peripheral tissues (Greenspan, 1994; Taurog, 1991; Wolff, 1998). Excess iodide in the circulating blood prevents secretion of thyroid hormone and autoregulation of iodide maintains its homeostatic level in plasma (Wolff and Chaikoff, 1948). Circulating  $T_3$  is produced primarily from peripheral deiodination of  $T_4$  in liver, kidney, thyroid and pituitary (type I enzyme), and in other tissues such as skin, cerebral cortex and placenta (type II enzyme). Type I enzyme produces active  $T_3$ , while type II deiodinase generates biologically inactive reverse  $T_3$ . In addition, thyroxine is metabolized in liver by sulfation and glucuronidation of the phenolic hydroxyl group (Visser, 1994).

Thyroid stimulating hormone (TSH) produced in the pituitary gland influences iodide transport and regulates biosynthesis of thyroid hormones (Halmi, 1961). TSH stimulates the uptake of iodide by sodium iodide symporters and the organification and secretion of thyroid hormones ( $T_4$ and  $T_3$ ). This process is inhibited by excess iodide (Cavalieri, 1997). In adult rat studies (Caldwell *et al.*, 1995; Fisher *et al.*, 2000), ammonium perchlorate (AP) inhibited the uptake of iodide into the thyroid and led to increased serum TSH in response to decreasing circulating levels  $T_3$  and  $T_4$ . The thyroid gland can compensate by TSH-stimulated increase in uptake of

1

iodide. However, chronic stimulation by TSH can result in increased thyroid weight, goiter and hypothyroidism (Fukuda *et al.*, 1975; Gerber *et al.*, 1981).

The objective of this study was to investigate the temporal relationships between administered perchlorate dose, concentration of circulating perchlorate in serum, and inhibition of the uptake of iodide in the thyroid gland. Inhibition of uptake of iodide in the thyroid was examined in rats dosed intravenously with perchlorate or given drinking water treated with perchlorate. A portion of this work was reported elsewhere (Fisher *et al.*, 2000).

#### **METHODS**

#### Chemicals

Ammonium perchlorate (99.8%), sodium iodide (99.5%), sodium hydroxide (99.99%) and trichloroacetic acid (98%) were purchased from Aldrich (Milwaukee, WI). Carrier-free <sup>125</sup>I (16.0mCi/ $\mu$ g) was purchased from Amersham Pharmacia Biotech (Piscataway, NJ). Water used in this study was treated by a reverse osmosis system and then deionized.

#### Animals

Male Sprague Dawley rats  $(310 \pm 30g)$  used throughout the experiments were obtained from Charles River Laboratories, Wilmington, MA. They were kept in separate cages and allowed access to commercial rat chow (Formulab, 5008) and water *ad libitum*. Rats used for urine collection were individually placed in metabolism cages; water and powdered food were freely available. Six rats were used per group in the kinetic studies and, for the thyroid hormone studies, eight rats were used per group.

Unless mentioned otherwise, intravenous dosing was carried out via lateral tail vein injection (volume = 0.67 mL/kg) of carrier-free <sup>125</sup>I and non-radiolabeled iodide (carrier) mixed in physiological saline, providing a total concentration of 33  $\mu$ g iodide/kg. Controls received 0.67 mL/kg of physiological saline. Schedules for *iv* administration and euthanization of rats by CO<sub>2</sub> asphyxiation were always in the morning (5:30-11:30 am) to minimize the influence of diurnal variation on thyroid hormone levels in serum.

#### **Animal Studies**

For the following studies, the term total iodine includes "bound iodine plus free iodide"; free iodide refers to "free inorganic iodide". <sup>125</sup>I is referred to as "carrier-free iodide" unless otherwise called "<sup>125</sup>I with carrier", which refers to <sup>125</sup>I plus non-radiolabeled iodide.

#### **Intravenous Dosing Studies**

<sup>125</sup>I and <sup>125</sup>I with Carrier: Rats (n = 6 per time point) were administered a single *iv* tail vein injection once with physiological saline (control group) or 33  $\mu$ g/kg <sup>125</sup>I (with carrier) in physiological saline. They were euthanized by CO<sub>2</sub> asphyxiation at 5, 15 and 30 minutes (min), 1, 2, 6, 9 and 24 hours (h) post dosing to collect thyroid and blood from the vena cava. Rats for the 24 h time point were placed individually in metabolism cages for up to 96 h to collect urine. Another group of rats (n=6 per time point) were injected with 2.6 ng/kg of <sup>125</sup>I in physiological saline and euthanized at 5, 15 and 30 min, 1, 2 and 6 h post dosing. Thyroid and blood were harvested.

*Perchlorate with* <sup>125</sup>*I* (with Carrier) Challenge: Rats (n=6 per dose and per time point) were injected with one of five doses of perchlorate (0.0, 0.01, 0.1, 1.0 and 3.0 mg/kg). At 2 h post dosing, they were challenged with <sup>125</sup>I with carrier (33  $\mu$ g/kg) by intravenous injection and euthanized at 5, 15 and 30 min, 1, 2, 6, 9 and 24 h post dosing of iodide. This corresponds to 2.08, 2.25, 2.5, 3, 4, 8, 11 and 26 h, respectively, after dosing with perchlorate. Blood and thyroid were harvested from all time point groups; urine was collected from rats in the 24 h dose group. Perchlorate and iodide levels were determined in the thyroid, serum and urine.

*Perchlorate with Thyroid Hormone Profile:* The highest *iv* dose of perchlorate (3 mg/kg) was chosen for a single *iv* dosing study to investigate the temporal relationship between inhibition of iodide uptake in the thyroid and biosynthesis of TSH and thyroid hormones. Rats (n=8 per dose and per time point) were injected with either perchlorate (3 mg/kg) or saline (control) and euthanized at 8, 12, 24 and 48 h post dosing. Perchlorate, TSH and thyroid hormones were measured in serum.

#### **Drinking Water Studies**

*Perchlorate with* <sup>125</sup>*I* (*with Carrier*) *Challenge*: To investigate the inhibitory effects of perchlorate, three drinking water studies (1, 5 and 14 days) were performed at different levels of perchlorate with target concentrations of 0.0, 1.0, 3.0 and 10.0 mg/kg-day continually exposed via drinking water. At the end of day 1, 5 or 14, rats (n=6 per group) were challenged once with 33  $\mu$ g/kg <sup>125</sup>I with carrier and euthanized at 2 h post iodide dosing. Blood and thyroid gland were collected for perchlorate and iodide analyses in serum.

*Perchlorate with Thyroid Hormone Profile:* Three groups of rats (n=8) were continually exposed via drinking water at different levels of perchlorate for 1, 5 and 14 days with target concentrations of 0.0, 0.1, 1.0, 3.0, and 10.0 mg/kg-day. They were euthanized at the end of the experiments and blood was collected for analysis of thyroid hormones and TSH levels in serum.

#### **Analytical Procedures**

### <sup>125</sup>I with Carrier Analysis in Tissues

Thyroid lobes were weighed and one or two lobes were placed in a 0.2 mL-micro tissue homogenizer (Kontes Glass Co., Vineland, NJ) and homogenized with 100  $\mu$ L of water. Thyroid homogenate was transferred into a polystyrene, round bottom tube (12 m x 75 mm). The micro tissue homogenizer was washed 3 times with 120  $\mu$ L of water to ensure complete transfer of the homogenate. Total radioactivity of the thyroid homogenate was counted by a  $\gamma$ -counter (Packard Instrument Co., Meriden, CT). Half a milliliter of 10% trichloroacetic acid (TCA) was then added to precipitate protein. The homogenate was vortexed for 2 to 3 seconds, centrifuged for 10 min at 5000 rpm, and the supernatant was transferred into a polystyrene tube. Half a milliliter of 5% TCA was added to the pellet. The pellet was gently dislodged and shaken. The mixture was centrifuged and decanted as above. Using half a milliliter of 2.5% TCA, the centrifuge procedure was again repeated. Radioactivity of the supernatant (free) and the pellet (bound) was measured by a  $\gamma$ -counter.

Aliquots of serum or urine were placed into a round polystyrene tube and total radioactivity was determined by a  $\gamma$ -counter. Free and bound radioactivity measurements of serum or urine was carried out in the same manner as described for thyroid homogenate.

High Pressure Liquid Chromatography (HPLC) Analysis of Perchlorate: Thyroid specimens from control and perchlorate dosed rats were homogenized in 250  $\mu$ L of deionized water in a micro tissue homogenizer. Homogenates were centrifuged at 31,500 x G for 30 min at 4°C. The supernatants were diluted 10, 25, 50 and 100 times with water bringing the final volume to 2 mL. The diluted supernatants were filtered through 0.45  $\mu$ m non-sterile acrodisc syringe filters provided with versapor (supported acrylic copolymer) membranes (Pall Gelmann Laboratory, Ann Arbor, MI). One mL of each filtrate was injected into the HPLC system using an autosampler.

Perchlorate analyses of serum and urine samples were carried out by mixing 100  $\mu$ L samples with 300  $\mu$ L ice-cold ethanol. The mixture was centrifuged at 31,500 x G for 30 min at 4°C. Supernatants were evaporated to dryness under nitrogen at 37°C and reconstituted in 2 mL of water. Reconstituted serum and urine samples were filtered as above for thyroid samples. One mL of each filtrate was injected into the HPLC.

*HPLC Conditions:* Analyses were performed with a Model Dx-300 liquid chromatographic system equipped with a background conductivity suppressor (Dionex, Sunnyvale, CA). The system consists of an advanced gradient pump (AGP standard size), conductivity detector (CDM-3), an anion self regenerating suppressor (ASRS 4mm) for the reduction of the background conductivity of the eluent, an autosampler (AS-3500), a 1000  $\mu$ L sample loop, a computer interface (ACI), and software (Autolon 450). Separation by isocratic elution of perchlorate was performed on a Dionex AS11 analytical column (4 x 250 mm) preceded by a Dionex AG 11 guard column (4 x 50 mm). The sensitivity of the detector was maintained between 0.5 and 100  $\mu$ s depending on the concentration. The mobile phase (flow rate = 1 mL) was 100 mM sodium hydroxide in water. The mobile phase was filtered through a 0.45  $\mu$ m filter provided with a nylon membrane (Micron Separations Inc., Westboro, MA), and degassed under vacuum before use. Perchlorate standards were prepared in water in the range of 0.5 to 100 ng/mL.

Analysis of TSH and Thyroid Hormones: The hormone assays were conducted using radioimmunoassay (RIA) kits following the manufacturers' instructions. Kits for T<sub>4</sub>, free T<sub>4</sub> and T<sub>3</sub> were purchased from Diagnostic Product Corp. (Los Angeles, CA) and kits for TSH from Amersham Corp. (Arlington Heights, IL). Standards and samples were run in triplicate and assay kits from the same batch number and with the same expiration date were used for all thyroid hormones or TSH measurements for each animal. Tracer <sup>125</sup>I activity was measured with a  $\gamma$ -counter.

Batch numbers and expiration dates for the kits are as follows.

- Total T<sub>4</sub> kits (T<sub>4</sub> calibrators batch # CT43, expired Dec 31, 2000; <sup>125</sup>I T<sub>4</sub> batch # TT42, expired July 31, 1999; T<sub>4</sub>-coated tubes batch # TT41, expired Jan 31, 2000)
- Free T<sub>4</sub> kits (free T<sub>4</sub> calibrators batch # F4C-8, expired Oct 31, 2000; <sup>125</sup>I free T<sub>4</sub> batch # TF42; expired July 31, 1999; free T<sub>4</sub> Ab-coated tubes batch # Tf41 Feb 29, 2000)
- Canine T<sub>3</sub> kits (canine T<sub>3</sub> calibrators batch # C3D3-8, expired July 31, 1999; <sup>125</sup>I canine T<sub>3</sub> batch #, TC32, expired July 31, 1999; canine T<sub>3</sub> Ab-coated tubes batch # TC31, expired Oct 31, 1999)
- TSH kits (TSH assay system code RPA554, batch # 104A, expired 23 Jul 1999)

#### **Statistical Analysis**

In single dose *iv* studies, two-tailed two-sample t-tests were used to compare the control group and dose group. In the studies with multiple dose groups, a one-way analysis of variance was performed to determine whether there was a significant difference among groups. All paired . tests among groups used two-tailed two-sample t-tests. All statistical comparisons utilized a minimum significance level of p < 0.05.

#### RESULTS

#### Intravenous Administration of Iodide and Perchlorate

The highest concentration of plasma iodide observed in rats dosed with 33  $\mu$ g/kg <sup>125</sup>I (with carrier) was 5.5-6  $\mu$ g/100 mL serum. This dose was selected to investigate iodide kinetics in male rats. The time course for the <sup>125</sup>I (2.6 ng/kg) and for 33  $\mu$ g/kg <sup>125</sup>I (with carrier) in the thyroid produced similar results for uptake in the thyroid. Figure 1 shows the percentage of bound iodide in the thyroids of rats dosed with <sup>125</sup>I (2.6 ng/kg) as compared to the thyroids of rats dosed with <sup>125</sup>I plus carrier (33 $\mu$ g/kg). Iodide uptake into the thyroid gland was very rapid and variable among individual rats during the first five minutes after dosing. At 1 h, about 90% of the administered dose was bound in the thyroid for both dose groups.

The time courses for perchlorate concentrations in the thyroid and serum are shown in Figures 2 and 3, respectively. At 2 hours and 5 minutes post dosing, thyroid concentrations of perchlorate at 0.01, 0.1, 1.0 and 3.0 mg/kg were 0.3, 2.64, 20.26 and 23.28  $\mu$ g/g thyroid, respectively. Table 1 shows estimated half-lives of terminal phases for perchlorate in the thyroid and serum. As measured by bound <sup>125</sup>I, perchlorate-induced inhibition of <sup>125</sup>I uptake in the thyroid was 13, 24, 70 and 88% at 2 h and 11, 29, 55 and 82% at 9 h after dosing with <sup>125</sup>I with carrier for the 0.01, 0.1, 1.0 and 3.0 mg/kg dose groups, respectively (Table 2).

Mean urinary excretion ( $\pm$  SD) of perchlorate over a 24 h period was about 97% ( $\pm$  2), 72% ( $\pm$  1), 87% ( $\pm$  17) and 91%( $\pm$  13) of the administered *iv* dose for the 0.01, 0.1, 1.0 and 3.0 mg/kg dose groups, respectively.




Figure 1. Percentages of bound iodine in the thyroid of male rats dosed with  $^{125}I$  (carrier-free) and  $^{125}I$  with carrier. Data are mean  $\pm$  SD (n=6).




Figure 2. Perhclorate levels in thyroid of male rats after single iv injection of perchlorate. Data are mean  $\pm$  SD (n=6).

Perchlorate Dose (mg/kg)	Thyroid	Serum
0.01	9	12
0.1	27	20
1.0	33	26
3.0	71	16

# TABLE 1. HALF-LIVES (HOURS) OF TERMINAL PHASESOF PERCHLORATE IN THE THYROID AND SERUM




Figure 3. Perchlorate levels in serum of male rats after single iv injection of perchlorate. Data are mean  $\pm$  SD (n=6).

TABLE 2.	PERCENT INHIBITION OF IODIDE UPTAKE IN THE THYROID GLAND
	OF MALE RATS (N=6) DOSED WITH PERCHLORATE

Time Points	Perchlorate Dose	Mean [lodide]	% of
	(mg/kg)	(µg/g)	Inhibition*
2 h	Control**	24.4	-
	0.01	21.3	13
	0.1	18.6	24
	1+	7.4	70
	3+	3.0	88
6 h	Control**	46.5	-
	0.01	36.7	21
	0.1	32.0	31
	1+	19.2	59
	3+	9.1	80
9 h	Control**	55.0	-
	0.01	49.2	11
	0.1+	39.2	29
	1+	24.7	55
	3+	10.0	82

\* Percent of inhibition = (control mean – dose mean)\*100/(control mean)
\*\*Dosed with <sup>125</sup>I with carrier only (33 µg/kg)
\* Significantly different from control at p<0.05</li>

Figure 4 depicts the inhibition time course of iodide uptake into the thyroid gland by perchlorate. The most pronounced inhibitory effects were at the 1 and 3 mg/kg perchlorate dose groups. By 24 h after dosing with <sup>125</sup>I (26 hours after dosing with AP), the inhibitory effects of perchlorate on <sup>125</sup>I uptake in the thyroid were still observed in the 1.0 and 3.0 mg/kg perchlorate dose groups (43 and 69%, respectively).






Figure 4. Total iodine levels in the thyroid of male rats after a single *iv* injection of perchlorate followed by an *iv* injection of  $^{125}$ I with carrier at 2 hours later. Data are mean  $\pm$  SD (n=6).


Figure 5 shows a time course of free iodide levels in the serum of rats injected intravenously with perchlorate. Since iodide levels of control, 0.01, 0.1, 1.0 and 3.0 mg/kg group were similar, only the control and 3 mg/kg dose groups are shown. The major route of elimination of iodide is urinary excretion (Perlman *et al.*, 1941). In our study, the control <sup>125</sup>I (with carrier) dosed rats excreted 89.5% ( $\pm$  5.5) of their <sup>125</sup>I dose over a 24 hour period (mean $\pm$ (SD)). The 0.01, 0.1, 1.0 and 3.0 mg/kg perchlorate dose groups excreted 87% ( $\pm$  7.8), 86% ( $\pm$  4.5), 88% ( $\pm$  0), and 84% ( $\pm$  7) of the <sup>125</sup>I dose in urine, respectively, over a 24 hour period (mean ( $\pm$  SD)). No bound iodide was detected in urine of rats dosed with <sup>125</sup>I (with carrier).





13

Serum TSH levels increased 50 to 60% above controls by 12 hours and remained elevated until termination of the study (48 hours) while Serum  $T_4$  concentrations decreased by about 20 to 30% from 12 to 24 hours (Fig. 6).  $T_3$  levels returned to normal by 24 h post dosing.  $T_4$  and free  $T_4$  levels returned to normal range by 48 h post dosing. Thyroid hormone levels returned to control values and serum levels of TSH remained elevated at 48 h.




Serum

Figure 6. Levels of serum TSH and thyroid hormones of rats after *iv* injection of perchlorate (3mg/kg). Data are mean  $\pm$  SD (n=8). \*Significantly different from control at p<0.05.

#### Perchlorate drinking water studies

In the perchlorate drinking water studies, concentrations of free iodide in serum of rats were similar (0.03 to 0.058  $\mu$ g/mL) to those seen in the single <sup>125</sup>I (with carrier) dosing study mentioned above. Inhibition of iodide uptake into thyroid by perchlorate is shown in Figure 7. There was a dose-related inhibition in the one-day treated group. The longer the rats were exposed to AP (i.e., 5 to 14 days), the fewer the inhibitory effects were observed. The thyroid gland appears to accommodate to longer-term perchlorate exposure, leading to no inhibitory effects at the end of the two-week drinking water study (except in the 10 mg/kg-day dose group).






Figure 8 depicts hormonal changes during perchlorate exposure in drinking water. In all treated groups, regardless of dose or the length of exposure time, TSH levels were increased. The serum  $T_4$  levels initially decreased in all dose groups except the lowest (0.01mg/kg-day); by 14 days, the 0.1 and 1.0 mg/kg-day dose groups returned to control  $T_4$  values. On day one, free  $T_4$  levels increased in all dose groups; by day five they returned to control levels. By day 14, however, free  $T_4$  levels in all dose groups were elevated, except in the 0.1mg/kg-day group.




Figure 8. Hormonal changes by perchlorate in repeated doses at 0, 0.1, 1, 3 and 10 mg/kg-day for 1, 5 and 14 days exposure. Data are mean values (n=8). \*Significantly different from control at p<0.05.

#### DISCUSSION

Tissue dosimetry of <sup>125</sup>I with carrier and perchlorate is essential to understand the effect of perchlorate on iodide uptake into thyroid. Target concentrations of <sup>125</sup>I with carrier and perchlorate in tissues, not administered doses, are needed to develop a pharmacokinetic model. Several kinetic studies of these compounds have been reported in the literature. However, the majority of these are reported as a ratio of tissue (e.g., thyroid) versus plasma concentration of radiolabeled iodide and/or perchlorate (Chow *et al.*, 1969; Chow and Woodbury, 1970; Wollman and Reed, 1959).

The thyroid gland has the ability to regulate uptake of excessive levels of iodide in the blood (Wolff-Chaikoff effect), which is one of the factors other than TSH that control iodide transfer into thyroid (Galton and Pitt-Rivers, 1959; Halmi *et al.*, 1956; Wolff, 1964). Wolff and Chaikoff (1948) reported that no autoregulation was observed when rats were dosed with 50  $\mu$ g/kg iodide, while doses of 250  $\mu$ g/kg iodide and higher resulted in autoregulation. The inhibition was correlated with plasma iodide concentration and the effective values were found to be above 20 to 35  $\mu$ g/100mL. Our dose of 33  $\mu$ g/kg of <sup>125</sup>I with carrier did not appear to cause the Wolff-Chaikoff effect.

Short-term perturbations of thyroid iodine economy by perchlorate and corresponding hormonal changes were investigated. Perchlorate is actively taken up by the thyroid gland and prevents iodide uptake into the thyroid, disrupting thyroid hormone synthesis and secretion (Anbar et al., 1959; Capen 1996; Chow et al., 1969; Wolff, 1998). Since perchlorate competitively inhibits iodide uptake into the thyroid, less iodide is available for organification. This results in lower concentrations of bound iodide in the thyroid gland thus lowering circulating levels of thyroid hormones. Reduction of circulating serum T<sub>4</sub> levels signals the pituitary gland to produce more TSH (D'Angelo et al., 1976). TSH increases TSH receptors in the thyroid gland and activates the thyroid. The half-life of plasma  $T_4$  is shorter (12 to 24 hours in rats) as compared to human  $T_4$  (5 to 9 days) due to the different binding proteins (Vranckx *et al.*, 1994). In humans, circulating T<sub>4</sub> is bound to thyroxine-binding globulin (TBG) which is virtually undetectable in rats after eight weeks of age (Savu et al., 1987; Vranckx et al., 1994). In rats, T<sub>4</sub> binds predominantly to albumin and its binding affinity is far less than TBG (approximately 1000 times lower); (Capen, 1996). Differences in transport proteins and their affinity to the thyroid hormones result in different half-lives for thyroid hormone in the rat and human. In the rat, serum concentrations of circulating thyroid hormones after perchlorate exposure can be quickly depleted. This results in increased production of TSH. Therefore, the rat thyroid has a greater potential to develop hyperplasia.

Our data revealed that free  $T_4$  and TSH levels increased in both single *iv* dose and drinking water studies. Perchlorate may displace thyroxine when it is bound to serum proteins resulting in elevation of free thyroxine levels (Yamada, 1967; Wolff, 1998). This may explain why free  $T_4$  levels increased in the presence of perchlorate.

In the drinking water studies, the shorter the exposure period, the greater the percent inhibition of iodide uptake. By two weeks, there was no inhibition except at the 10 mg/kg-day dose. Levels of bound iodide in controls and dosed rats, except the highest dose group, were similar after two

weeks of AP exposure. Perchlorate-induced inhibitory effects of iodide uptake in the thyroid were dose- and time-dependent.

 $T_4$  levels in the drinking water studies significantly decreased at most of the time points and TSH levels increased during the same time. Perturbation of thyroid hormone synthesis by perchlorate caused decreased  $T_4$  levels, which resulted in increased TSH (negative feedback) and free  $T_4$  in our studies.

We report dose-related inhibition of thyroid iodide uptake after a single *iv* dose of perchlorate, and both dose- and time- dependent changes in inhibition of thyroid iodide uptake in perchlorate drinking water studies. Urinary excretion was the major route of elimination of iodide and perchlorate. In both the single dose and drinking water studies, TSH and free T<sub>4</sub> serum levels were elevated while T<sub>4</sub> serum levels decreased. Serum T<sub>3</sub> levels in the drinking water studies remained unchanged in all dosing groups. These data demonstrate that upregulation of the thyroid is rapid and can compensate for the inhibitory effects of perchlorate.

#### REFERENCES

Anbar M., Guttmann S, and Lewitus Z. (1959). The mode of action of perchlorate ions on the iodine uptake of the thyroid gland. *Int. J. Appl. Radiat. Isot.* **7**, 87-96.

Caldwell DJ, King JH, Kinkead ER, Wolfe RE, Narayanan L and Mattie DR. (1995). Results of a fourteen day oral-dosing toxicity study of ammonium perchlorate. In: Proceedings of the 1995 JANNAF safety and environmental protection subcommittee meeting: Volume 1; December; Tampa, FL. Columbia, MD: Chemical Propulsion Information Agency Publication 634.

Capen CC. (1996). Toxic responses of the endocrine system. In: Casarett & Doull's Toxicology: Klaasen ed. McGraw-Hill, New York, pp. 617-640.

Carrasco N. (1993). Iodide transport in the thyroid gland. Biochim. Biophys. Acta 1154, 65-82.

Cavalieri R. (1997). Iodine metabolism and thyroid physiology: current concepts. *Thyroid* 7, 177-181.

Chow SY, Chang LR, and Yen MS. (1969). A comparison between the uptake of radioactive perchlorate and iodide by rat and guinea pig thyroid glands. *J. Endocrinol.* **45**, 1-8.

Chow SY, and Woodbury DM. (1970). Kinetics of distribution of radioactive perchlorate in rat and guinea-pig thyroid glands. *J. Endocrinol.* 47, 207-218.

D'Angelo SA, Paul DH, Wall NR and Lombard DM. (1976). TSH rebound phenomenon and kinetics of secretion in the goitrous rat: Differential effects of thyroxine on synthesis and release of 'TSH. *Endocrinology* **99**, 935-943.

Eskandari S, Loot DD, Dai G, Levy O, Wright E and Carrasco N. (1997). Thyroid Na<sup>+</sup>/I symporter. J. Biol. Chem. **272**, 27230-27238.

Fisher J, Todd P, Mattie D, Godfrey R, Naraynan L & Yu K. (2000). Preliminary development of a physiological model foe perchlorate in the adult male rat: A framework for further studies. *Drug Chem. Toxicol.* 23, 243-258.

Fukuda H, Yasuda N and Greer MA. (1975). Changes in plasma thyroglobulin, thyroxine, and triiodothyronine after acute or chronic administration of iodide to iodine-deficient rats. *Endocrinology* **97**, 1196-1204.

Galton V, and Pitt-Rivers R. (1959). The effect of excessive iodine on the thyroid of the rat. *Endocrinology* **64**, 835-839.

Gerber H, Studer H, Conti A, Engler H, Kohler H and Haeberl A. (1981). Reaccumulation of thyroglobulin and colloid in rat and mice thyroid follicles during intense thyrotropin stimulation. *J. Clin. Invest.* **68**, 1338-47.

Goldman SJ and Stanbury JB. (1973). The metabolism of perchlorate in the rat. *Endocrinology* **92**, 1536-1538.

Greenspan FS. (1994). The Thyroid Gland in the Basic & Clinical Endocrinology, Greenspan and Baxter, eds, 4<sup>th</sup> ed, pp.160-168, Appleton & Lange, Norwalk.

Halmi NS. (1961). Thyroidal transport. Vitam. Horm. 19, 133-163.

Halmi NS, Stuelke RG, and Schnell MD. (1956). Radioiodide in the thyroid and in other organs of rats treated with large doses of perchlorate. *Endocrinology* **58**, 634-650.

Nunez J and Pommier L. (1982). Formation of thyroid hormones. Vitam. Horm. 39, 175-229.

Perlman I, Chaikoff IL and Morton ME. (1941). Radioactive iodide as an indicator of the metabolism of iodine. J. Biol. Chem. 139, 433-447.

Savu L, Vranckx R, Maya M and Nunez EA. (1987). A thyroxine-binding globulin (TBG)-like protein in the sera of developing and adult rats. *Biochem. Biophys. Research Comm.* **992**, 379-384.

Taurog A. (1991). Hormone synthesis and secretion, in Werner and Ingbar's The Thyroid. Braverman and Utiger eds, 7<sup>th</sup> ed. pp47-81. Lippincott-Raven, Philadelphia.

Visser TJ. (1994). Sulfation and glucuronidation pathways of thyroid hormone metabolism. In: Thyroid Hormone Metabolism: Molecular Biology and Alternative Pathways. Wu & Visser (eds) pp 85-117. CRC Press, Boca Raton. Vranckx R, Rouaze-Romet M, Savu L, Mechighel P, Maya M and Nunez EA. (1994). Regulation of rat thyroxine-binding globulin and transthyretin: Studies in thyroidectomized and hypophysectomized rats given triiodothyronine and growth hormone. *J. Endocrinol.* **142**, 77-84.

Wolff J. (1964). Transport of iodide and other anions in the thyroid gland. *Physiol. Rev.* 44, 45-90.

Wolff J. (1998). Perchlorate and the thyroid gland. *Pharmacol. Rev.* 50, 89-105.

Wolff J and Chaikoff IL. (1948). Plasma inorganic iodide as a homeostatic regulator of thyroid function. J. Biol. Chem. 174, 555-564.

Wolff J and Maurey J. (1961). Thyroidal iodide transport, II. Comparison with non-thyroid iodide-concentrating tissues. *Biochim. Biophys. Acta* 47, 467-474.

Wollman SH, Reed FE. (1959). Transport of radioiodide between thyroid gland and blood in mice and rats. *Am. J. Physiol.* **196**, 113-120.

Yamada T. (1967). Effects of perchlorate and other anions on thyroxine metabolism in the rat. *Endocrinology.* **81**, 1285-1290.